Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.
about
Interleukin 2 receptor antagonists for kidney transplant recipientsTarget of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipientsCurrent state of renal transplant immunosuppression: Present and futureOedema, solid organ transplantation and mammalian target of rapamycin inhibitor/proliferation signal inhibitors (mTOR-I/PSIs)Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial.More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study.Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.Efficacy and safety of basiliximab in kidney transplantation.Use of Neoral C monitoring: a European consensus.Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients.Everolimus: an immunosuppressive agent in transplantation.Severe psoriasis treated with a new macrolide: everolimus.Can mTOR inhibitors reduce the risk of late kidney allograft failure?Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month resultsEverolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment.Everolimus: preventing organ rejection in adult kidney transplant recipients.Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients.Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions.Immunological risks of minimization strategies.The safety of calcineurin inhibitors for kidney-transplant patients.Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.Limitations of the interpretation and extrapolation of clinical trial data in kidney transplant recipients.mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study.Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12).The use of everolimus in renal-transplant patientsAssociation of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.Suppression of cytomegalovirus-specific CD8(+)T cells by everolimus.Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation.Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages.Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis.Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients.
P2860
Q24240492-6FEC0513-18A9-48B6-B472-E09517BDAC77Q24246340-2D768FCC-452A-4D1A-93B3-D28E1772B413Q26829789-31E65645-45C4-4AAD-BDFF-BF069AD3209AQ26851935-359E44A8-B969-4B19-AB50-763A6A724285Q31138722-112E9539-76D9-40E6-AC50-114FC34FD2FEQ33806121-CB27CF04-E12C-4E50-8947-AFBA8A86151DQ34023028-F139A71A-D50B-4AF3-BF18-18FE9EAC4C3FQ34805919-4A4C3A15-678B-49D7-8FC4-030316D6D3E8Q35236076-BF58CE94-B887-4F0F-855C-F31EB466AC3AQ35669138-0817CA19-01D9-4AA3-B975-1C4C07F1D439Q35819373-E16CD3FC-2424-4E13-8A8D-2C7F7EE4A5BAQ36150553-7F51A6F2-7DCC-4FF1-958C-36D8BB569CEAQ36158864-AAB701BA-D8B0-4A73-82C7-47132E8B3EA2Q36505748-8DDCF81D-1659-44B0-A0FD-B4AE9AA73D07Q36521866-267292FA-C5C9-4919-9EE8-EB8FC4991DAFQ36708370-6836D92D-65FD-43F3-A25F-4A5AD968BF45Q36884566-40E052AA-7323-490D-9779-F5BB8C7FAC44Q37033275-C4E816EF-9510-41D0-830F-8AFED644396DQ37793095-5A059D3B-155B-4E0C-ABFB-3D0A1D3A4038Q37873950-B21F6D48-1C2D-4C45-94A0-8EF612B6FD6AQ37992135-332888C2-C40A-46FB-8BC5-7D50AB900DE6Q38241710-01A54E8D-0A49-4740-A024-5F0ACA265240Q38254279-CD2001D6-FDFA-4A42-B17A-4187C94C0639Q38391150-FF818894-59C4-4885-92A7-BE450068F697Q38578386-851E5611-187E-4695-939F-03410A26BF38Q38668601-0267FBD6-3DAB-4BB7-AAD5-4DA20745682EQ38700286-5F9AE901-5F64-4184-A356-8CD283450477Q38962103-775B81CB-80BF-45FA-9211-7BEC7ABA4004Q40132359-84E00994-C97D-447C-992F-43B7840473CFQ40961859-A0759759-9FF3-4552-9670-5FD813EF2ADAQ41859603-C61AF7EE-EE89-4FEA-8D65-47929B2FC96DQ42069171-7ED97119-42DC-4BE9-8887-56B4D1B9FAECQ42284856-7840D7D5-C817-4E57-9933-988B44C07BADQ43071206-BEDF22E9-CA44-44E4-AA2A-6B8557E65889Q43485988-170855B7-B0D4-4C06-A824-0B50A2385600Q43583466-0D2CBD75-47C3-4875-BD64-D4D4AFAE51D7Q43673379-AD99A4DF-EF6C-4F0F-8713-F1A57F7DB160Q43826756-9CB3E1AF-CC11-4DC4-B08C-342D835745B3Q44709602-AE3F911C-8817-452A-85D1-4B3C9FAC5942Q46542215-8F596E72-6DA2-41B7-863C-CAE043AC14B5
P2860
Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Everolimus with optimized cycl ...... lts of two randomized studies.
@ast
Everolimus with optimized cycl ...... lts of two randomized studies.
@en
Everolimus with optimized cycl ...... lts of two randomized studies.
@nl
type
label
Everolimus with optimized cycl ...... lts of two randomized studies.
@ast
Everolimus with optimized cycl ...... lts of two randomized studies.
@en
Everolimus with optimized cycl ...... lts of two randomized studies.
@nl
prefLabel
Everolimus with optimized cycl ...... lts of two randomized studies.
@ast
Everolimus with optimized cycl ...... lts of two randomized studies.
@en
Everolimus with optimized cycl ...... lts of two randomized studies.
@nl
P2093
P2860
P1476
Everolimus with optimized cycl ...... lts of two randomized studies.
@en
P2093
Annette Jappe
Bernard Bourbigot
Gentil Alves Filho
Giovanni Civati
Helio Tedesco
Johanna Geissler
John C Magee
John Leone
John Whelchel
Josette Eris
P2860
P304
P356
10.1111/J.1600-6143.2004.00389.X
P407
P577
2004-04-01T00:00:00Z